Head-to-head · Cost-Efficiency Index
NuuVim vs Fitish
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NuuVim
Cost-first shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
Visit NuuVimFitish
Shoppers who want a genuinely all-in price with no separate consult fee, or a fixed low-dose 'microdose' option.
Visit FitishThe verdict
NuuVim takes it, leading the Cost-Efficiency Index 70 to 69. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound. Fitish still earns a C — Shoppers who want a genuinely all-in price with no separate consult fee, or a fixed low-dose 'microdose' option.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NuuVim.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NuuVim | Fitish |
|---|---|---|
| Cost-Efficiency Index | 70/100 | 69/100 |
| Semaglutide / mo | $79/mo (all doses, 3-mo plan, new patients only, compounded) | $219/mo (microdose tier, plus a separate fee, compounded) |
| Tirzepatide / mo | $133/mo (all doses, 3-mo plan, new patients only, compounded) | $339/mo (microdose tier, compounded) |
| Semaglutide / yr (modeled) | $948 | $2,628 |
| Tirzepatide / yr (modeled) | $1,596 | $4,068 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Yes | Yes |
| Rank here | #88 | #92 |
NuuVim
70/100Where the value is
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
The tradeoffs
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
Fitish
69/100Where the value is
- Price genuinely includes consult, medication, and shipping — confirmed in the product page's own text, not just marketing copy
- A real microdose tier exists at a meaningfully lower fixed price for both drugs
- Injectable and oral tablet formats both offered
The tradeoffs
- No stated minimum commitment or cancellation terms found on the product pages
- No named prescriber, medical director, or specific compounding pharmacy
Regulatory note: the FDA issued a warning letter to FITISH in June 2026. We still list and link to Fitish; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.